EA201790796A8 - НОВОЕ 5,6-ДИГИДРО-4H-БЕНЗО[b]ТИЕНО-[2,3-d]АЗЕПИНОВОЕ ПРОИЗВОДНОЕ - Google Patents

НОВОЕ 5,6-ДИГИДРО-4H-БЕНЗО[b]ТИЕНО-[2,3-d]АЗЕПИНОВОЕ ПРОИЗВОДНОЕ

Info

Publication number
EA201790796A8
EA201790796A8 EA201790796A EA201790796A EA201790796A8 EA 201790796 A8 EA201790796 A8 EA 201790796A8 EA 201790796 A EA201790796 A EA 201790796A EA 201790796 A EA201790796 A EA 201790796A EA 201790796 A8 EA201790796 A8 EA 201790796A8
Authority
EA
Eurasian Patent Office
Prior art keywords
thieno
benzo
derivative
digidro
azepin
Prior art date
Application number
EA201790796A
Other languages
English (en)
Other versions
EA201790796A1 (ru
Inventor
Саймон Фрейзер Хант
Стюарт Томас Онионз
Владимир Шербухин
Юэн Александер Фрейзер Фордайс
Питер Джон Мюррей
Дэниел Уильям Брукс
Кадзухиро Ито
Питер Стронг
Мэттью Стивен Коутс
Original Assignee
Палмосайд Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Палмосайд Лимитед filed Critical Палмосайд Лимитед
Publication of EA201790796A1 publication Critical patent/EA201790796A1/ru
Publication of EA201790796A8 publication Critical patent/EA201790796A8/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Представлено 5,6-дигидро-4H-бензо[b]тиено-[2,3-d]азепиновое производное (как определено в раскрытии), которое пригодно в лечении РСВ-инфекции и для профилактики заболевания, связанного с РСВ-инфекцией.
EA201790796A 2014-10-10 2015-10-08 НОВОЕ 5,6-ДИГИДРО-4H-БЕНЗО[b]ТИЕНО-[2,3-d]АЗЕПИНОВОЕ ПРОИЗВОДНОЕ EA201790796A8 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14188494 2014-10-10
PCT/GB2015/052944 WO2016055791A1 (en) 2014-10-10 2015-10-08 Novel 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative

Publications (2)

Publication Number Publication Date
EA201790796A1 EA201790796A1 (ru) 2017-09-29
EA201790796A8 true EA201790796A8 (ru) 2018-10-31

Family

ID=51842340

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790796A EA201790796A8 (ru) 2014-10-10 2015-10-08 НОВОЕ 5,6-ДИГИДРО-4H-БЕНЗО[b]ТИЕНО-[2,3-d]АЗЕПИНОВОЕ ПРОИЗВОДНОЕ

Country Status (13)

Country Link
US (6) US9732098B2 (ru)
EP (2) EP3204389B1 (ru)
JP (2) JP6675407B2 (ru)
KR (1) KR20170058921A (ru)
CN (1) CN106852144B (ru)
AU (1) AU2015329789B2 (ru)
BR (1) BR112017005104B1 (ru)
CA (1) CA2957868C (ru)
EA (1) EA201790796A8 (ru)
IL (1) IL250823A0 (ru)
MX (1) MX2017004652A (ru)
SG (1) SG11201701184WA (ru)
WO (2) WO2016055791A1 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017004652A (es) 2014-10-10 2017-06-19 Pulmocide Ltd Novedoso derivado de 5,6-dihidro-4h-benzo[b]tieno-[2,3-d]azepina.
WO2016097761A1 (en) 2014-12-18 2016-06-23 Pulmocide Limited 4,5-dihydro-6h-thieno[3,2-d]benzazepine derivatives and their use to treat respiratory syncytial virus (rsv) infections
AU2016297024B2 (en) 2015-07-22 2021-03-04 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as RSV inhibitors
EP3402799B1 (en) 2016-01-15 2022-05-04 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
KR20180108598A (ko) * 2016-02-03 2018-10-04 얀센 사이언시즈 아일랜드 유씨 Rsv의 치료를 위한 조합 생성물
WO2017175000A1 (en) * 2016-04-08 2017-10-12 Pulmocide Limited Compounds
US10398706B2 (en) 2017-01-06 2019-09-03 Enanta Pharmaceuticals, Inc. Heteroaryldiazepine derivatives as RSV inhibitors
EP3582784B1 (en) 2017-02-16 2022-06-08 Enanta Pharmaceuticals, Inc. Processes for the preparation of benzodiazepine derivatives
WO2018226801A1 (en) 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as rsv inhibitors
WO2019006291A1 (en) * 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
WO2019006295A1 (en) * 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
WO2019067864A1 (en) 2017-09-29 2019-04-04 Enanta Pharmaceuticals, Inc. PHARMACEUTICAL AGENTS IN COMBINATION AS INHIBITORS OF RSV
CA3080138A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives
WO2019094920A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as rsv inhibitors
WO2019199908A1 (en) * 2018-04-11 2019-10-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
MX2021011144A (es) 2019-03-18 2022-01-18 Enanta Pharm Inc Derivados de las benzodiazepinas como inhibidores del vsr.
WO2020210246A1 (en) * 2019-04-09 2020-10-15 Enanta Pharmaceuticals, Inc, Heterocyclic compounds as rsv inhibitors
MX2022003984A (es) 2019-10-04 2022-07-27 Enanta Pharm Inc Compuestos heterociclicos antivirales.
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
US11534439B2 (en) 2020-07-07 2022-12-27 Enanta Pharmaceuticals, Inc. Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
US11945830B2 (en) 2021-02-26 2024-04-02 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693635A (en) 1993-07-29 1997-12-02 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
JP2002543065A (ja) 1999-04-28 2002-12-17 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ppap受容体リガンドとしてのトリアリール酸誘導体
CA2711644A1 (en) * 2008-01-07 2009-07-16 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US8999969B2 (en) 2009-07-09 2015-04-07 Gilead Sciences, Inc. Anti-RSV compounds
ES2749504T3 (es) 2009-10-13 2020-03-20 Ligand Pharm Inc Compuestos de moléculas pequeñas miméticos del factor de crecimiento hematopoyético y sus usos
KR101764952B1 (ko) 2010-07-29 2017-08-03 리겔 파마슈티칼스, 인크. Ampk-활성화 헤테로시클릭 화합물 및 그의 사용 방법
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
SG11201700851WA (en) 2014-08-05 2017-03-30 Alios Biopharma Inc Combination therapy for treating a paramyxovirus
MX2017004652A (es) * 2014-10-10 2017-06-19 Pulmocide Ltd Novedoso derivado de 5,6-dihidro-4h-benzo[b]tieno-[2,3-d]azepina.
EP3402799B1 (en) 2016-01-15 2022-05-04 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
KR20180108598A (ko) 2016-02-03 2018-10-04 얀센 사이언시즈 아일랜드 유씨 Rsv의 치료를 위한 조합 생성물
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
WO2019006291A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS

Also Published As

Publication number Publication date
IL250823A0 (en) 2017-04-30
CA2957868C (en) 2023-02-28
US9732098B2 (en) 2017-08-15
EP3204389B1 (en) 2019-06-26
US20170355717A1 (en) 2017-12-14
SG11201701184WA (en) 2017-03-30
US10273249B2 (en) 2019-04-30
US10472375B2 (en) 2019-11-12
AU2015329789B2 (en) 2019-09-26
US20170190718A1 (en) 2017-07-06
CA2957868A1 (en) 2016-04-14
US10189863B2 (en) 2019-01-29
BR112017005104A2 (pt) 2017-12-05
US20180319820A1 (en) 2018-11-08
EP3204388A1 (en) 2017-08-16
BR112017005104B1 (pt) 2022-08-23
JP6675407B2 (ja) 2020-04-01
US9926335B2 (en) 2018-03-27
KR20170058921A (ko) 2017-05-29
WO2016055792A1 (en) 2016-04-14
JP2017531038A (ja) 2017-10-19
EA201790796A1 (ru) 2017-09-29
CN106852144A (zh) 2017-06-13
MX2017004652A (es) 2017-06-19
EP3204389A1 (en) 2017-08-16
AU2015329789A1 (en) 2017-03-09
WO2016055791A1 (en) 2016-04-14
EP3204388B1 (en) 2018-12-12
JP2017531039A (ja) 2017-10-19
US10035810B2 (en) 2018-07-31
US20190202841A1 (en) 2019-07-04
US20170305935A1 (en) 2017-10-26
CN106852144B (zh) 2019-08-30
US20180179228A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
EA201790796A8 (ru) НОВОЕ 5,6-ДИГИДРО-4H-БЕНЗО[b]ТИЕНО-[2,3-d]АЗЕПИНОВОЕ ПРОИЗВОДНОЕ
IL251285A0 (en) 3-substituted 5-amino-h6-triazolo[5,4-d]pyrimidine-7,2-dione compounds for the treatment and prevention of viral infection
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
UA118759C2 (uk) Сполуки 3,4-дигідроізохінолін-2(1н)-ілу
CL2017001661A1 (es) Compuestos biciclicos fusionados para el tratamiento de una enfermedad.
EA201992832A1 (ru) Подкожное введение adamts13
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
CY1121709T1 (el) Παραγωγο τετραϋδροπυρρολο[3,4-d][1,3]θειαζινης ως αναστολεας της bace
EP3446199A4 (en) MODIFICATION OF CONTEXT OF REQUESTS
EA201692250A1 (ru) Конденсированные спироциклические гетероароматические соединения для лечения бактериальных инфекций
DK3148588T3 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease
AU2015221431A8 (en) Novel 6,7-dihydro-3H-oxazolo[3,4-a]pyrazine-5,8-dione derivative compounds
UA115756C2 (uk) ЗАСТОСУВАННЯ 3-АРИЛАМІНОМЕТИЛ-6,7,8,9-ТЕТРАГІДРО-5H-[1,2,4]ТРИАЗОЛО[4,3-а]АЗЕПІНІВ ЯК АНАЛЬГЕТИКІВ
UA99994U (ru) 2,4-диамино-5-имино-8-оксо-10-(2-хлорфенил)-3-циано-7,8,9,10-тетрагидро-5н-пиридо[2',3':2,3]тиопирано[4,5-b]пиридин
UA104459U (ru) Применение лактопротеина с сорбитолом как цитопротектора аденогипофиза при ожоговой болезни.
RU2014115449A (ru) N-карбэтоксиметилимидазо[4,5-e]бензо[1,2-c;3,4-c']дифуроксан
TH1601002954A (th) ออกตะไฮโดร-ไซโคลบิวตะ[1,2-c;3,4-c']ไดไพร์โรล-2-อิล ใหม่
PH12015502305A1 (en) Use of pidotimod to treat inflammatory bowel disease
EA201692164A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом
UA111273C2 (uk) Ліофілізований препарат для ін'єкцій
UA96814U (uk) Спосіб лікування онкологічних захворювань
UA86579U (en) 2-AMINO-4-METHYL-9-(1-NAPHTHYL)-7-OXO-3-CYANO-6,7,8,9-TETRAHYDROPYRIDO[3',2':4,5]THIENO[3,2-b]PYRIDINE
TH1501004831A (th) อนุพันธ์เตตระไฮโดรอิมมิดาโซ[1,5-d][1,4]ออกซาชีพีน
UA96409U (uk) Спосіб реабілітації жінок після перенесеного сальпінгоофориту